Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). "This medication has a novel ...

CIDP significantly affects daily life, with many patients needing mobility aids and caregiver support, impacting employment and quality of life. A real-world survey showed 22% of CIDP patients were ...

VYVGART HYTRULO faces a new FDA safety signal related to CIDP, but I believe this is not a major concern for the franchise. The main issue is the transition from IVIg to VYVGART HYTRULO in real-world ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration ...